Total Payments
$1.4M
2024 Payments
$147,217
Companies
73
Transactions
4,136
Medicare Patients
60,215
Medicare Billing
$8.7M
Payment Breakdown by Category
Other$657,547 (45.9%)
Consulting$387,099 (27.0%)
Research$169,998 (11.9%)
Travel$146,921 (10.2%)
Food & Beverage$70,725 (4.9%)
Education$1,479 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $581,731 | 297 | 40.6% |
| Consulting Fee | $387,099 | 131 | 27.0% |
| Unspecified | $169,998 | 138 | 11.9% |
| Travel and Lodging | $146,921 | 339 | 10.2% |
| Honoraria | $72,317 | 29 | 5.0% |
| Food and Beverage | $70,725 | 3,177 | 4.9% |
| Grant | $3,500 | 1 | 0.2% |
| Education | $1,479 | 24 | 0.1% |
Payments by Type
General
$1.3M
3,998 transactions
Research
$169,998
138 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $189,776 | 686 | $0 (2024) |
| PFIZER INC. | $186,987 | 392 | $0 (2024) |
| Lilly USA, LLC | $143,233 | 233 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $128,488 | 315 | $0 (2024) |
| GENZYME CORPORATION | $95,196 | 144 | $0 (2024) |
| UCB, Inc. | $91,261 | 273 | $0 (2024) |
| Eli Lilly and Company | $85,841 | 35 | $0 (2024) |
| GlaxoSmithKline, LLC. | $57,209 | 166 | $0 (2024) |
| Celgene Corporation | $54,274 | 168 | $0 (2019) |
| Amgen Inc. | $44,656 | 327 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $147,217 | 506 | ABBVIE INC. ($38,897) |
| 2023 | $109,372 | 418 | ABBVIE INC. ($45,395) |
| 2022 | $129,222 | 439 | ABBVIE INC. ($39,051) |
| 2021 | $142,907 | 375 | PFIZER INC. ($53,466) |
| 2020 | $120,858 | 437 | Lilly USA, LLC ($26,691) |
| 2019 | $290,221 | 689 | Lilly USA, LLC ($47,909) |
| 2018 | $283,374 | 668 | Eli Lilly and Company ($30,582) |
| 2017 | $210,599 | 604 | PFIZER INC. ($30,736) |
All Payment Transactions
4,136 individual payment records from CMS Open Payments — Page 1 of 166
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $33.33 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Immunology | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $61.64 | General |
| Category: Immunology | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $0.73 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/18/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: Bone Health | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $0.88 | General |
| Category: Immunology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $1.17 | General |
| Category: Immunology | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.19 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $4.41 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $0.11 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| Category: Immunology | ||||||
| 12/05/2024 | SOBI, INC | KINERET (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3041658 IN PATIENTS WITH SKIN DISEASES | Eli Lilly and Company | $36,037 | 1 |
| TANEZUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $12,420 | 11 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $11,000 | 4 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 16 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN TNFI EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $10,505 | 1 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $9,387 | 2 |
| INVIGORATE | Novartis Pharmaceuticals Corporation | $7,143 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LY3337641 IN ADULT SUBJECTS WITH RHEUMATOID ARTHRITIS: THE RAJUVENATE STUDY | Eli Lilly and Company | $5,130 | 1 |
| A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $4,979 | 1 |
| A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB IN PREFILLED SYRINGES TO DEMONSTRATE THE EFFICACY AT 24 WEEKS AND TO ASSESS THE LONG TERM EFFICACY SAFETY AND TOLERABILITY UP TO 5 YEARS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS | Novartis Pharmaceuticals Corporation | $3,570 | 1 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $3,068 | 1 |
| A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who | SANOFI-AVENTIS U.S. LLC | $2,935 | 3 |
| FASINUMAB CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $2,470 | 1 |
| A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3361237 IN HEALTHY SUBJECTS | Eli Lilly and Company | $2,467 | 2 |
| INVIGORATE-1 | Novartis Pharmaceuticals Corporation | $2,370 | 1 |
| A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS. | UCB, Inc. | $2,300 | 1 |
| A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEK | UCB, Inc. | $2,300 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $2,162 | 1 |
| A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO | GlaxoSmithKline, LLC. | $2,053 | 13 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | Eli Lilly and Company | $1,866 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS | Eli Lilly and Company | $1,797 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | Regeneron Pharmaceuticals, Inc. | $1,743 | 9 |
| A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $1,740 | 2 |
| A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS OA OF THE KNEE. | Noven Pharmaceuticals, Inc. | $1,704 | 2 |
| Publication support research related | Novartis Pharma AG | $1,688 | 1 |
| Long-term effect of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment | SANOFI-AVENTIS U.S. LLC | $1,664 | 2 |
| ISB 830 | Ichnos Sciences Inc. | $1,500 | 1 |
| CC-10004-PSA-005 | Celgene Corporation | $1,488 | 1 |
| CAIN457P12301 | Novartis Pharmaceuticals Corporation | $1,357 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly Export S.A. Puerto Rico Branch | $1,313 | 1 |
| A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequa | SANOFI-AVENTIS U.S. LLC | $1,294 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,285 | 2 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH ANKYLOSING SPONDYLITIS | UCB, Inc. | $1,240 | 3 |
| CAIN457P12302 | Novartis Pharmaceuticals Corporation | $1,221 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,200 | 2 |
| Long-Term Safety of Sarilumab in Rheumatoid Arthritis: An Integrated Analysis with up to 7 Years? Follow-Up | SANOFI-AVENTIS U.S. LLC | $1,162 | 2 |
| CC-292-RA-001 - A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy with Methotrexate in Active Rheumatoid Arthritis | Celgene Corporation | $1,156 | 1 |
| PROFILE: PROspective sarilumab (preFILled syringe/pen) multinationaL obsErvational Study | GENZYME CORPORATION | $1,149 | 1 |
| Efficacy and Safety of Sarilumab in Combination with csDMARDs or as Monotherapy in Subpopulations of Patients with Moderately to Severely Active Rheumatoid Arthritis in Three Phase III Randomized, Con | SANOFI-AVENTIS U.S. LLC | $1,147 | 2 |
| Long-Term Safety with Sarilumab Monotherapy or with csDMARDs in Rheumatoid Arthritis: An Integrated Analysis of over 8,000 Patient-Years Follow-Up | SANOFI-AVENTIS U.S. LLC | $1,061 | 1 |
| A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | ABBVIE INC. | $1,000 | 1 |
| MOBILITY-TARGET MONARCH Pooled Subpopulations | SANOFI-AVENTIS U.S. LLC | $922.53 | 1 |
| EASY | SANOFI-AVENTIS U.S. LLC | $820.21 | 2 |
| Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis 2-Year Results from a Phase 2b Dose-Ranging Study and its Open-Label Extension | UCB, Inc. | $820.00 | 1 |
| Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and its Open-Label Extension | UCB, Inc. | $820.00 | 1 |
| Long-Term Effect of Sarilumab Plus Methotrexate on Disease Activity, Physical Function, Radiographic Progression, and Safety: A 5-Year Analysis | SANOFI-AVENTIS U.S. LLC | $804.00 | 2 |
| A multi-center, uncontrolled extension study evaluating the efficacy and safety of sarilumab in patients with active Rheumatoid Arthritis (SARIL-RA-EXTEND) | SANOFI-AVENTIS U.S. LLC | $754.80 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis | SANOFI US SERVICES INC. | $676.21 | 10 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $600.01 | 1 |
| Similar efficacy and safety of sarilumab 150 mg or 200 mg q2w regardless of primary or secondary failure with TNF inhibitors | SANOFI-AVENTIS U.S. LLC | $532.95 | 1 |
| Sarilumab as Monotherapy or in Combination with Conventional Synthetic DMARDs in Patients with RA: 12-Week Treatment Results from a Multicenter, Open-Label, Prospective, Single-Arm Observational Study | SANOFI-AVENTIS U.S. LLC | $454.29 | 1 |
| A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | Regeneron Pharmaceuticals, Inc. | $450.32 | 1 |
| CC-10004-PSA-004 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis and a | Celgene Corporation | $442.00 | 1 |
| Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY) | SANOFI-AVENTIS U.S. LLC | $423.87 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF THE PREFILLED SAFETY SYRINGE OR AUTO-INJECTOR FOR THE SUBCUTANEO | UCB, Inc. | $420.00 | 1 |
| EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY | UCB, Inc. | $420.00 | 1 |
| EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY | UCB, Inc. | $420.00 | 1 |
| Efficacy and Safety of Bimekizumab in Ankylosing Spondylitis 48-Week Patient-Reported Outcomes from a Phase 2b, Randomised, Double-blind, Placebo-Controlled, Dose-Ranging Study | UCB, Inc. | $420.00 | 1 |
| Efficacy and Safety of Bimekizumab in Ankylosing Spondylitis: 48-Week Patient-Reported Outcomes from a Phase 2b, Randomised, Double-blind, Placebo-Controlled, Dose-Ranging Study | UCB, Inc. | $420.00 | 1 |
| A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequa | SANOFI-AVENTIS U.S. LLC | $409.08 | 1 |
| A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $330.80 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $294.00 | 1 |
| Sarilumab as Monotherapy or in Combination With Conventional Synthetic DMARDs in Patients With RA: 12-Week Treatment Results From a Multicenter, Open-Label, Prospective, Single-Arm Observational Study | SANOFI-AVENTIS U.S. LLC | $292.50 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY OF SECUKINUMAB TO COMPARE 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO ARE RANDOMIZED TO DOSE ESCALATION AFTER NOT ACHIEVING INACTIVE DISEASE DURING AN INITIAL 16 WEEK OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG(ASLEAP) | Novartis Pharmaceuticals Corporation | $238.00 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $215.00 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of | SANOFI-AVENTIS U.S. LLC | $213.06 | 1 |
| Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment | SANOFI-AVENTIS U.S. LLC | $205.70 | 1 |
| Long-Term Effect of Sarilumab Plus Methotrexate on Disease Activity, Physical Function and Radiographic Progression: A 5-Year Analysis | SANOFI-AVENTIS U.S. LLC | $104.94 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $104.58 | 1 |
| MOBILITY | SANOFI-AVENTIS U.S. LLC | $71.34 | 1 |
| To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY) | SANOFI-AVENTIS U.S. LLC | $46.81 | 1 |
| Fasinumab Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $43.84 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN475 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | Regeneron Pharmaceuticals, Inc. | $33.21 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 97 | 13,748 | 238,750 | $7.5M | $2.1M |
| 2022 | 102 | 14,704 | 235,627 | $7.6M | $2.2M |
| 2021 | 101 | 15,540 | 214,178 | $6.8M | $2.2M |
| 2020 | 97 | 16,223 | 234,808 | $6.5M | $2.2M |
Total Patients
60,215
Total Services
923,363
Medicare Billing
$8.7M
Procedure Codes
397
All Medicare Procedures & Services
397 procedure records from CMS Medicare Utilization — Page 1 of 16
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 24 | 12,925 | $1.0M | $435,833 | 42.2% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 41 | 97,200 | $1.7M | $380,812 | 23.0% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 18 | 70,313 | $704,032 | $328,187 | 46.6% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 33 | 23,464 | $1.2M | $247,964 | 20.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 87 | 7,800 | $312,000 | $143,785 | 46.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 672 | 1,166 | $213,175 | $102,501 | 48.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 104 | 519 | $155,700 | $46,460 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 467 | 619 | $94,779 | $36,723 | 38.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 42 | 490 | $67,130 | $25,260 | 37.6% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2023 | 22 | 1,888 | $72,000 | $24,955 | 34.7% |
| J7322 | Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 2023 | 24 | 1,560 | $47,502 | $20,423 | 43.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 182 | 378 | $103,224 | $18,712 | 18.1% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 177 | 1,017 | $109,836 | $17,669 | 16.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 141 | 141 | $37,365 | $14,701 | 39.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 841 | 1,635 | $73,567 | $13,701 | 18.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 881 | 1,790 | $142,788 | $13,443 | 9.4% |
| 86480 | Tuberculosis test, gamma interferon | Office | 2023 | 179 | 181 | $28,596 | $10,872 | 38.0% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 159 | 303 | $43,565 | $8,244 | 18.9% |
| 77085 | Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | Office | 2023 | 166 | 166 | $75,525 | $8,189 | 10.8% |
| 84460 | Liver enzyme (sgpt), level | Office | 2023 | 759 | 1,553 | $68,322 | $7,963 | 11.7% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 178 | 193 | $41,877 | $7,807 | 18.6% |
| 84450 | Liver enzyme (sgot), level | Office | 2023 | 759 | 1,554 | $68,366 | $7,799 | 11.4% |
| 82565 | Blood creatinine level | Office | 2023 | 757 | 1,542 | $64,754 | $7,655 | 11.8% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 751 | 1,514 | $105,968 | $7,603 | 7.2% |
| 86147 | Cardiolipin antibody (tissue antibody) measurement | Office | 2023 | 91 | 282 | $34,968 | $6,891 | 19.7% |
About Dr. Alan Kivitz, MD
Dr. Alan Kivitz, MD is a Rheumatology healthcare provider based in Duncansville, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1447259023.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Kivitz, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $147,217 received in 2024. These payments were reported across 4,136 transactions from 73 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($581,731).
As a Medicare-enrolled provider, Kivitz has provided services to 60,215 Medicare beneficiaries, totaling 923,363 services with total Medicare billing of $8.7M. Data is available for 4 years (2020–2023), covering 397 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Duncansville, PA
- Active Since 07/18/2005
- Last Updated 04/27/2017
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1447259023
Products in Payments
- TALTZ (Drug) $129,868
- XELJANZ (Drug) $107,356
- KEVZARA (Drug) $105,799
- COSENTYX (Biological) $97,198
- RINVOQ (Biological) $97,110
- Otezla (Drug) $81,010
- BENLYSTA (Biological) $53,379
- KEVZARA SARILUMAB INJECTION (Biological) $47,755
- KRYSTEXXA (Drug) $43,184
- Bimzelx (Biological) $41,462
- KEVZARA (Biological) $35,633
- Humira (Biological) $30,157
- SKYRIZI (Biological) $30,060
- Zilretta (Drug) $26,997
- Cimzia (Drug) $21,235
- OLUMIANT (Drug) $21,113
- KRYSTEXXA (Biological) $18,291
- COSENTYX (Drug) $15,278
- SIMPONI ARIA (Biological) $15,076
- AIN457H (Biological) $14,116
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.